Experion Holdings Ltd. (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31), formerly Viridium Pacific Group the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of Cannabis and EFX Laboratories Inc., a medical product’s production and and clinical research company based in Calgary, AB. is pleased to provide an update on its core business strategy and operational activities.

Mr. Jay Garnett, Chief Executive Officer, commented, “Over the past weeks, we have made great strides executing our focused strategy on key initiatives that will best position Experion to be a significant player in the cannabis space. We believe that as the cannabis industry matures, the market will reward focused companies that can monetize their assets. This paradigm shift is starting to show as investors are becoming focused on companies that are charting a path to profitability. We are placing a strong focus on the medical cannabis segment, where we see an un-matched market opportunity, both domestically and internationally.”


Highlights discussed in the update:

  • Experion’s entry into the Hemp-CBD market
  • Experion expands national footprint signs Quebec Letter of Intent
  • Experion’s Product Update – Recreational and Health and Wellness
  • Experion’s Medical Cannabis Focus Update
  • Experion – CEO Podcast Interview with Equity Guru “Experion Holdings and the Art of Executive Accountability”

To read the Update on Commercial and Operations Activities in full and listen to the CEO Podcast Interview, please visit: www.experionwellness.com/experion-provides-update-on-commercial-and-operations-activities

About Experion Holdings Ltd.

Experion Holdings Ltd. is the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of Cannabis, based in Mission, BC; and EFX Laboratories Inc., a medical products production and clinical research company based in Calgary, AB.

Experion Holdings Ltd. is invested in a portfolio of products to address a wide spectrum of consumer needs’ including Medical, Adult-use, and Wellness and Therapeutic products.

Experion Holdings Ltd trades on the TSX Venture Exchange as a Tier 1 issuer under the symbol “EXP” on the OTCQB Venture under the symbol “EXPFF” and on the Frankfurt Stock Exchange under the symbol “MB31”

For further information, please visit the Company’s website www.experionwellness.com or join our Global Investor Forum on 8020 http://connects.company/ExperionEXP where you can read all press releases or contact Investor Relations directly.

Judy-Ann Pottinger, Investor Relations Manager
Phone: 604- 617-5290
Email: judy-ann@experionwellness.com

Disclosure

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

SOURCE

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis extractor, announced today that the Canadian Intellectual Property Office has granted the Company a patent for the acetylation of cannabinoids. More specifically, the patent covers a process for acetylating cannabidiol (“CBD”), and subsequent refinement of CBD-O-Acetate using a proprietary extraction and distillation technique.

Keep reading... Show less

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) The Company announces that it has recently negotiated an extension to its option to purchase another 21% of Arcology for another year by an investment of $1,000,000. If the company exercises that option, it would then own 51

The Company is clarifying that in its press release of January 15th regarding the signing of a definitive agreement to acquire bit mining infrastructure, that the first phase will deliver 9,450 terahash per second, not 9,450 petahash as stated.

Keep reading... Show less

Appointment of Philip Young as CEO and director adds a seasoned executive with a track record of new device and therapeutics development, FDA/regulatory approvals, capital markets, M&A and operational success

 Lobe Sciences Ltd (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Mr. Philip J. Young as Chief Executive Officer, Corporate Secretary and a director of the Company, effective January 15, 2021. Mr. Young replaces Thomas Baird, who resigned as CEO as of the same date.

Keep reading... Show less

2020 Program Focused on Building Local Communities

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), one of the largest vertically integrated, multistate cannabis operators in the United States, announced today its employees volunteered over 5,000 service hours during a seven-month period in 2020 as part of Cresco’s “Make a Difference” initiative.

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less